

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER: 20-031/S-026

APPROVAL LETTER



NDA 20-031/S-026

GlaxoSmithKline
Attention: Thomas F. Kline
Assistant Director, U.S. Regulatory Affairs
1250 S. Collegeville Rd.
P.O. Box 5089
Collegeville, PA 19426

Dear Mr. Kline:

Please refer to your supplemental new drug application dated April 28, 2000, received April 28, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Paxil® (paroxetine hydrochloride) Tablets.

We acknowledge receipt of your submissions dated March 14, 2001 (revised draft labeling).

Your submission of March 14, 2001 constituted a complete response to our February 26, 2001 action letter.

This supplemental new drug application provides for the use of Paxil® (paroxetine hydrochloride) Tablets for the treatment of generalized anxiety disorder as a new indication.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert submitted on March 14, 2001).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-031/S-026." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an

assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have not fulfilled the requirements of 21 CFR 314.55 (or 601.27). We are deferring submission of your pediatric studies. However, in the interim, please submit your pediatric drug development plans within 120 days from the date of this letter unless you believe a waiver is appropriate. Within approximately 120 days of receipt of your pediatric drug development plan, we will review your plan and notify you of its adequacy.

If you believe that this drug qualifies for a waiver of the pediatric study requirement, you should submit a request for a waiver with supporting information and documentation in accordance with the provisions of 21 CFR 314.55 within 60 days from the date of this letter. We will notify you within 120 days of receipt of your response whether a waiver is granted. If a waiver is not granted, we will ask you to submit your pediatric drug development plans within 120 days from the date of denial of the waiver.

Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products (pediatric exclusivity). You should refer to the *Guidance for Industry on Qualifying for Pediatric Exclusivity* (available on our web site at www.fda.gov/cder/pediatric) for details. If you wish to qualify for pediatric exclusivity you should submit a "Proposed Pediatric Study Request" (PPSR) in addition to your plans for pediatric drug development described above. We recommend that you submit a Proposed Pediatric Study Request within 120 days from the date of this letter. If you are unable to meet this time frame but are interested in pediatric exclusivity, please notify the division in writing. FDA generally will not accept studies submitted to an NDA before issuance of a Written Request as responsive to a Written Request. Sponsors should obtain a Written Request before submitting pediatric studies to an NDA. If you do not submit a PPSR or indicate that you are interested in pediatric exclusivity, we will review your pediatric drug development plan and notify you of its adequacy. Please note that satisfaction of the requirements in 21 CFR 314.55 alone may not qualify you for pediatric exclusivity. FDA does not necessarily ask a sponsor to complete the same scope of studies to qualify for pediatric exclusivity as it does to fulfill the requirements of the pediatric rule.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you should have any questions, please call Ms. Anna Marie Homonnay, R.Ph., Regulatory Project Manager, at (301) 594-5535.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER: 20-031/S-026

APPROVABLE LETTER

NDA 20-031/S-026

GlaxoSmithKline
Attention: Thomas Kline
Assistant Director, U.S. Regulatory Affairs
1250 S. Collegeville Road
P.O. Box 5089
Collegeville, PA 19426

Dear Mr. Kline:

Please refer to your supplemental new drug application dated April 28, 2000, received April 28, 2000 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Paxil® (paroxetine hydrochloride) Tablets.

We acknowledge receipt of your submissions dated June 16, and October 4 and 13, 2000.

This supplemental new drug application provides for the use of Paxil® Tablets for generalized anxiety disorder (GAD).

We have completed the review of this application, as submitted with the draft labeling, and it is approvable. Before this application may be approved, however, it will be necessary for you to address the following:

Labeling

Accompanying this letter as an attachment is our proposal for the labeling of Paxil® Tablets for the generalized anxiety disorder indication. Please submit revised draft labeling identical in content to the enclosed labeling (text for the package insert). Explanations for our proposed changes are provided in the bracketed comments embedded within the proposed text. We would be happy to discuss these proposed changes in more detail through a teleconference if you wish.

Safety Update

Under 21 CFR 314.50(d)(vi)(b), we request that you provide a final safety update for Paxil® Tablets for GAD.

Regulatory Status Update

Please provide any new information on the worldwide regulatory status of Paxil® Tablets for GAD, including the status of all actions either taken or pending before foreign regulatory authorities.

World Literature Update

Prior to the approval of Paxil® Tablets for GAD, we will require an updated report on the world archival literature pertaining to the safety of this product for this indication.

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

Within 10 days after the date of this letter, you are required to amend the supplemental application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

Under 21 CFR 314.102(d) of the new drug regulations, you may request an informal meeting or telephone conference with this division to discuss what further steps need to be taken before the application may be approved.

This product may be considered to be misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with these changes prior to approval of this supplemental application.

If you should have any questions, please call Ms. Anna Marie Homonnay, R.Ph., Regulatory Health Project Manager, at (301) 594-5535.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

35 page(s) of
revised draft labeling
has been redacted
from this portion of
the review.
